Akhtar M, Begum Y, Rahman S, Afrad M, Parvin N, Akter A
Front Public Health. 2024; 12:1484162.
PMID: 39726651
PMC: 11669683.
DOI: 10.3389/fpubh.2024.1484162.
Riaz S, Steinsland H, Hanevik K
Pathogens. 2020; 9(9).
PMID: 32872549
PMC: 7558491.
DOI: 10.3390/pathogens9090714.
Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A
Clin Vaccine Immunol. 2015; 23(1):55-64.
PMID: 26581889
PMC: 4711095.
DOI: 10.1128/CVI.00617-15.
Rocker J, DiPalma J, Pannell L
Dig Dis Sci. 2014; 60(1):24-31.
PMID: 25179492
DOI: 10.1007/s10620-014-3330-0.
Mansour A, Shaheen H, Amine M, Hassan K, Sanders J, Riddle M
J Clin Microbiol. 2014; 52(2):587-91.
PMID: 24478492
PMC: 3911313.
DOI: 10.1128/JCM.01639-13.
Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico.
Mohamed J, DuPont H, Flores J, Palur H, Nair P, Jiang Z
Clin Infect Dis. 2011; 52(11):1332-41.
PMID: 21596674
PMC: 3140174.
DOI: 10.1093/cid/cir228.
Case series study of traveler's diarrhea in U.S. military personnel at Incirlik Air Base, Turkey.
Porter C, Mohammady H, Baqar S, Rockabrand D, Putnam S, Tribble D
Clin Vaccine Immunol. 2008; 15(12):1884-7.
PMID: 18845833
PMC: 2593170.
DOI: 10.1128/CVI.00163-08.
Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
Lapa J, Sincock S, Ananthakrishnan M, Porter C, Cassels F, Brinkley C
Clin Vaccine Immunol. 2008; 15(8):1222-8.
PMID: 18579693
PMC: 2519302.
DOI: 10.1128/CVI.00491-07.
Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.
Coster T, Wolf M, Hall E, Cassels F, Taylor D, Liu C
Infect Immun. 2006; 75(1):252-9.
PMID: 17074855
PMC: 1828404.
DOI: 10.1128/IAI.01131-06.
Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention.
Qadri F, Svennerholm A, Faruque A, Sack R
Clin Microbiol Rev. 2005; 18(3):465-83.
PMID: 16020685
PMC: 1195967.
DOI: 10.1128/CMR.18.3.465-483.2005.
Prevalence of enterotoxigenic Escherichia coli strains harboring the longus pilus gene in Brazil.
Nishimura L, Giron J, Nunes S, Guth B
J Clin Microbiol. 2002; 40(7):2606-8.
PMID: 12089285
PMC: 120555.
DOI: 10.1128/JCM.40.7.2606-2608.2002.
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.
Guerena-Burgueno F, Hall E, Taylor D, Cassels F, Scott D, Wolf M
Infect Immun. 2002; 70(4):1874-80.
PMID: 11895950
PMC: 127863.
DOI: 10.1128/IAI.70.4.1874-1880.2002.
Type IV longus pilus of enterotoxigenic Escherichia coli: occurrence and association with toxin types and colonization factors among strains isolated in Argentina.
Pichel M, Binsztein N, Qadri F, Giron J
J Clin Microbiol. 2002; 40(2):694-7.
PMID: 11826000
PMC: 153402.
DOI: 10.1128/JCM.40.2.694-697.2002.
Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
Beignon A, Briand J, Muller S, Partidos C
Immunology. 2001; 102(3):344-51.
PMID: 11298834
PMC: 1783185.
DOI: 10.1046/j.1365-2567.2001.01183.x.
Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine.
Hall E, Wierzba T, Ahren C, Rao M, Bassily S, Francis W
Infect Immun. 2001; 69(5):2853-7.
PMID: 11292698
PMC: 98234.
DOI: 10.1128/IAI.69.5.2853-2857.2001.
Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees.
Wenneras C, Qadri F, Bardhan P, Sack R, Svennerholm A
Infect Immun. 1999; 67(12):6234-41.
PMID: 10569732
PMC: 97024.
DOI: 10.1128/IAI.67.12.6234-6241.1999.
Antibody responses in humans against coli surface antigen 6 of enterotoxigenic Escherichia coli.
Helander A, Wenneras C, Qadri F, Svennerholm A
Infect Immun. 1998; 66(9):4507-10.
PMID: 9712809
PMC: 108547.
DOI: 10.1128/IAI.66.9.4507-4510.1998.
Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139.
Qadri F, Jonson G, Begum Y, Wenneras C, Albert M, Salam M
Clin Diagn Lab Immunol. 1997; 4(4):429-34.
PMID: 9220159
PMC: 170545.
DOI: 10.1128/cdli.4.4.429-434.1997.
Epitope maps of the Escherichia coli heat-labile toxin B subunit for development of a synthetic oral vaccine.
Takahashi I, Kiyono H, Jackson R, Fujihashi K, Staats H, Hamada S
Infect Immun. 1996; 64(4):1290-8.
PMID: 8606092
PMC: 173917.
DOI: 10.1128/iai.64.4.1290-1298.1996.
Presence of secretory IgA antibodies to an enteric bacterial pathogen in human milk and saliva.
Nathavitharana K, Catty D, Raykundalia C, McNeish A
Arch Dis Child Fetal Neonatal Ed. 1995; 72(2):F102-6.
PMID: 7712266
PMC: 2528391.
DOI: 10.1136/fn.72.2.f102.